Military Awards Rx Bandz Auto-Injector Development Contract

The Department of War has tapped the New Jersey company to develop life-saving antibiotic injectors for combat zones.

Updated on Oct. 15, 2026 in Military

Isometric editorial illustration of a sterile medical injector device, evoking professional defense technology and medical innovation. — The US Department of War awarded Rx Bandz a contract to develop ruggedized, portable auto-injectors to treat battlefield infections efficiently. AI Illustration. Upload story photo >

Live Poll

Should medical device companies prioritize military research contracts over developing general civilian healthcare products?

The US Department of War has awarded an SBIR Phase I contract to Rx Bandz for the development of emergency medication auto-injectors. This initiative aims to address the high rate of infection among combat wounds in austere environments.

Why it matters

Delayed access to antibiotics significantly increases the medical burden and risk of death for wounded soldiers. Developing portable, effective delivery systems is a critical priority for military medical preparedness.

The US military currently maintains two existing five-year contracts with Rx Bandz valued at $23 million. The company's auto-injector technology is designed to deliver between 1 mL and 5 mL of therapeutics, including viscous biologics and hydrogels.

The players

Rx Bandz

A Denville, New Jersey-based medical technology firm that specializes in the manufacturing of the MiniJect auto-injector platform.

US Department of War

The federal agency responsible for overseeing national defense interests and awarding military research contracts.

The details

The Denville, New Jersey-based manufacturer will utilize its MiniJect platform to create ruggedized injectors capable of delivering life-saving medication. The company is currently progressing through a Series A equity funding round to support its ongoing development efforts.

October 15, 2026: Rx Bandz announced the new Department of War contract.
End of 2026: The company intends to submit its Device Master File to the FDA.

Political Context

This contract award follows the established framework of the Small Business Innovation Research (SBIR) program to accelerate private-sector technology for military use. Critics often argue over whether such sole-source or niche contracts provide enough competition for defense procurement funds.

While this contract directly impacts military medical readiness, the development of these delivery platforms could eventually influence civilian emergency medical supplies. Future FDA clearance of the device will determine its path toward wider adoption and availability.

The takeaway

Advancing medical delivery technology is a priority for mitigating battlefield mortality rates. The upcoming FDA submission marks a key milestone in moving this technology toward potential field use.